Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

Last updated: November 15, 2019
Sponsor: Allergan
Overall Status: Completed

Phase

3

Condition

Rosacea

Skin Wounds

Hives (Urticaria)

Treatment

N/A

Clinical Study ID

NCT02132117
199201-005
  • Ages > 18
  • All Genders

Study Summary

This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion

Exclusion Criteria:

  • Greater than 3 inflammatory lesions on the face

  • Current treatment with monoamine oxidase (MAO) inhibitors

  • Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma orSjogren's syndrome.

Study Design

Total Participants: 445
Study Start date:
June 01, 2014
Estimated Completion Date:
May 31, 2015

Connect with a study center

  • College Station, Texas
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.